These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24143122)

  • 1. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.
    Alken S; Kelly CM
    Cancer Manag Res; 2013 Oct; 5():357-65. PubMed ID: 24143122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel: a new active agent in the therapy of metastatic breast cancer.
    Fumoleau P; Seidman AD; Trudeau ME; Chevallier B; Ten Bokkel Huinink WW
    Expert Opin Investig Drugs; 1997 Dec; 6(12):1853-65. PubMed ID: 15989586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxanes for adjuvant treatment of early breast cancer.
    Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
    Vaishampayan U; Parchment RE; Jasti BR; Hussain M
    Urology; 1999 Dec; 54(6A Suppl):22-9. PubMed ID: 10606281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of taxanes in the adjuvant treatment of early stage breast cancer.
    Piccart M
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S25-34. PubMed ID: 12868803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systemic review of taxanes and their side effects in metastatic breast cancer.
    Lai JI; Chao TC; Liu CY; Huang CC; Tseng LM
    Front Oncol; 2022; 12():940239. PubMed ID: 36303832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxanes in the first-line chemotherapy of metastatic breast cancer: review.
    Friedrich M; Diesing D; Villena-Heinsen C; Felberbaum R; Kolberg HC; Diedrich K
    Eur J Gynaecol Oncol; 2004; 25(1):66-70. PubMed ID: 15053065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.
    Biganzoli L; Aapro M; Loibl S; Wildiers H; Brain E
    Cancer Treat Rev; 2016 Feb; 43():19-26. PubMed ID: 26827689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
    ten Bokkel Huinink WW; Prove AM; Piccart M; Steward W; Tursz T; Wanders J; Franklin H; Clavel M; Verweij J; Alakl M
    Ann Oncol; 1994 Jul; 5(6):527-32. PubMed ID: 7918124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis.
    Gubens MA; Wakelee HA
    Lung Cancer (Auckl); 2010; 1():63-76. PubMed ID: 28210107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
    O'Shaughnessy J
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 12):17-22. PubMed ID: 12435175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.